Merge pull request #6 from mikepsinn/v6

updated home page

Author: mikepsinn

01-problem.md

@@ -7,13 +7,14 @@ Additionally, [150,000](https://www.weforum.org/agenda/2020/05/how-many-people-d
 * [**FIFTY-ONE**](https://en.wikipedia.org/wiki/Casualties\_of\_the\_September\_11\_attacks) September 11th attacks every day
 * [**NINE**](https://en.wikipedia.org/wiki/Casualties\_of\_the\_September\_11\_attacks) Holocausts every year
 
-![deaths from disease](../img/deaths-from-disease-vs-deaths-from-terrorism-chart.png)
+![deaths from disease](https://static.crowdsourcingcures.org/img/deaths-from-disease-vs-deaths-from-terrorism-chart.png)
 
-**Will throwing more money at the existing healthcare system save us?**
+**Is throwing more money at the existing healthcare system the solution?**
 
 Since 2014, healthcare spending per person has been [increasing faster than ever](https://fred.stlouisfed.org/series/HLTHSCPCHCSA) before.
 
-![health spending](../img/us-healthcare-expenditure.svg)
+![health spending](https://static.crowdsourcingcures.org/img/us-healthcare-expenditure.svg)
+
 
 
 Despite this additional spending, life expectancy has actually been declining.
@@ -31,7 +32,7 @@ It costs [$41k](https://www.clinicalleader.com/doc/getting-a-handle-on-clinical-
 * The process takes over 10 years.
 * It costs [$36k](https://www.clinicalleader.com/doc/getting-a-handle-on-clinical-trial-costs-0001) per subject in Phase III clinical trials.
 
-![clinical trial cost](../img/cost-of-clinical-trials.png) [source: clinicalresearch.io](https://www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trials-breakdown/)
+![clinical trial cost](https://static.crowdsourcingcures.org/img/cost-of-clinical-trials.png) [source: clinicalresearch.io](https://www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trials-breakdown/)
 
 This high cost leads to the following problems:
 
@@ -41,7 +42,7 @@ We still know next to nothing about the long-term effects of 99.9% of the 4 poun
 
 Under the current system of research, it costs [$41k](https://www.clinicalleader.com/doc/getting-a-handle-on-clinical-trial-costs-0001#:\~:text=The%20clinical%20trials%20cost%20a,and%20benchmarking%20clinical%20trial%20costs.) per subject in Phase III clinical trials. As a result, there is not a sufficient profit incentive for anyone to research the effects of any factor besides a molecule that can be patented.
 
-![how much we know](../img/how-much-we-know.png)
+![how much we know](https://static.crowdsourcingcures.org/img/how-much-we-know.png)
 
 **Lack of Incentive to Discover the Full Range of Applications for Off-Patent Treatments**
 
@@ -87,7 +88,7 @@ Furthermore, patient sample sizes are very small. The number of subjects per tri
 * [70](https://www.ncbi.nlm.nih.gov/books/NBK50886/) patients per depression trial
 * [100](https://www.ncbi.nlm.nih.gov/books/NBK50886/) per diabetes trial
 
-![wellbutrin small sample size](../img/wellbutrin-effectiveness-small-sample-size.png)
+![wellbutrin small sample size](https://static.crowdsourcingcures.org/img/wellbutrin-effectiveness-small-sample-size.png)
 
 In the example in graphic above a drug is prescribed to millions of patients based on a study with only 36 subjects, where a representation of the general public is questionable.
 
@@ -114,7 +115,7 @@ have a ton of overlap in functionality representing [$157,500,000,000](https://w
 If this code was freely shared, everyone could build on what everyone else had done.
 Theoretically, this could increase the rate of progress by 350,000 times.
 
-![closed source competition vs open source collaboration](../img/closed-source-competition-vs-open-source-collaboration.sketch.png)
+![closed source competition vs open source collaboration](https://static.crowdsourcingcures.org/img/closed-source-competition-vs-open-source-collaboration.sketch.png)
 
 The obstacle has been the free-rider problem. Software Developers that open source their code give their closed-source competitors an unfair advantage.  This increases their likelihood of bankruptcy even higher than the 90% failure rate they already faced.
 

SITEMAP.md

@@ -0,0 +1,80 @@
+---
+title: DFDA Wiki Sitemap
+description: Comprehensive navigation structure for the DFDA Wiki
+lastUpdated: '2024-02-09'
+status: live
+---
+
+# DFDA Wiki Sitemap
+
+## Core Documentation
+- [Home](home.md) - Overview and main entry point
+- [README](README.md) - Project introduction and setup
+- [Implementation Plan](strategy/implementation-plan.md) - Execution strategy
+- [Roadmap](strategy/roadmap.md) - Development timeline and milestones
+
+## Regulatory Framework
+- [Disease Eradication Act](disease-eradication-act/disease-eradication-act.md)
+  - [Summary](disease-eradication-act/disease-eradication-act-summary.md)
+  - [Details](disease-eradication-act/disease-eradication-act-details.md)
+  - [Cost-Benefit Analysis](disease-eradication-act/disease-eradication-act-cost-benefit-analysis.md)
+- [Right to Trial Act](proposals/right-to-trial-act.md)
+- [Cure Acceleration Act](cure-acceleration-act.md)
+- [DFDA Executive Order](dfda-executive-order.md)
+
+## Economic Models
+- [Cost-Benefit Analyses](economic-models/)
+  - [Claude Analysis](economic-models/dfda-cost-benefit-analysis-claude-3.5-sonnet.md)
+  - [GPT Analysis](economic-models/dfda-cost-benefit-analysis-chatgpt-o1.md)
+  - [Gemini Analysis](economic-models/dfda-cost-benefit-analysis-gemini-2-thinking.md)
+  - [DeepSeek Analysis](economic-models/dfda-cost-benefit-analysis-deepseek-r1.md)
+  - [Perplexity Analysis](economic-models/dfda-cost-benefit-analysis-perplexity-r1.md)
+
+## Clinical Trials
+- [Protocols](clinical-trials/protocols/)
+  - [Crowdsourcing Research](clinical-trials/protocols/crowdsourcing-longevity-research.md)
+- [Decentralized Methods](clinical-trials/decentralized-methods/)
+  - [DeSci AI DAO](clinical-trials/decentralized-methods/desci-ai-dao.md)
+
+## Features & Plugins
+- [Root Cause Analysis](features/root-cause-analysis-plugin.md)
+- [Real-time Notifications](features/optomitron-real-time-notifications-plugin.md)
+- [Life Force Score NFT](features/life-force-score-nft.md)
+
+## AI Agents
+- [Study Review Agent](agents/study-review-agent.md)
+
+## Community
+- [Contributing Guide](community_directory/CONTRIBUTING.md)
+- [Projects](community_directory/projects/README.md)
+- [Patient Advocacy](community_directory/patient_advocacy/README.md)
+- [Open Source Projects](community_directory/open-source-projects/open-source-projects.md)
+- [Developers](community_directory/developers/README.md)
+
+## Benefits
+- [Patient Participation](benefits/patient-participation.md)
+- [Lower Drug Prices](benefits/lower-drug-prices.md)
+
+## Reference & Research
+- [Cost Barriers](reference/cost-barriers/)
+  - [Executive Summary](reference/cost-barriers/executive-summary/e2-analysis-of-costs.md)
+  - [Data Sources](reference/cost-barriers/21-data-sources.md)
+  - [Conceptual Framework](reference/cost-barriers/22-conceptual-framework.md)
+- [History of Medical Regulation](history-of-medical-regulation-and-clinical-research.md)
+- [History of the FDA](reference/history-of-the-fda.md)
+- [Problems in Clinical Research](problems-in-clinical-research.md)
+
+## Technical Documentation
+- [Data Standards](data-standards/)
+- [Analytics](analytics/)
+- [API Documentation](openapi-huge.yml)
+
+## Additional Resources
+- [Strategy Comparison](strategy/strategy-comparison.md)
+- [War on Disease Strategy](proposals/war-on-disease-strategy.md)
+- [Futarchy](futarchy.md)
+- [Privacy Policy](privacy.md)
+
+---
+
+*Note: This sitemap is automatically generated and maintained. Last updated: 2024-02-09* 

agents/study-review-agent.md

@@ -44,3 +44,11 @@
 
 - Accumulate and review existing placebo-controlled randomized experiments pertinent to the observed predictors and health outcomes.
 - Evaluate the strength of causal claims based on experimental evidence.
+
+## Safety Validation with LLM IRB
+
+- Implement a safety-validated fine-tuned large language model (LLM) to act as an Institutional Review Board (IRB).
+- Utilize the LLM IRB to evaluate study protocols for safety before proceeding with further review.
+- The LLM IRB will assess protocols based on established safety guidelines and ethical considerations.
+- Protocols will be submitted to the LLM IRB, which will provide a safety assessment, indicating whether the protocol is deemed safe or unsafe, and highlighting any potential safety concerns.
+- This safety validation step will be integrated into the beginning of the study review process to ensure that all studies are evaluated for safety before undergoing other forms of review.